Ren Fangbing, Ma Yanhui, Zhang Kexin, Luo Youhong, Pan Ruiyan, Zhang Jingwen, Kan Chengxia, Hou Ningning, Han Fang, Sun Xiaodong
Department of Endocrinology and Metabolism, Affiliated Hospital of Weifang Medical University, Weifang, China.
Clinical Research Center, Affiliated Hospital of Weifang Medical University, Weifang, China.
Medicine (Baltimore). 2024 May 3;103(18):e38023. doi: 10.1097/MD.0000000000038023.
Cancer remains a significant challenge in the field of oncology, with the search for novel and effective treatments ongoing. Calycosin (CA), a phytoestrogen derived from traditional Chinese medicine, has garnered attention as a promising candidate. With its high targeting and low toxicity profile, CA has demonstrated medicinal potential across various diseases, including cancers, inflammation, and cardiovascular disease. Studies have revealed that CA possesses inhibitory effects against a diverse array of cancers. The underlying mechanism of action involves a reduction in tumor cell proliferation, induction of tumor cell apoptosis, and suppression of tumor cell migration and invasion. Furthermore, CA has been shown to enhance the efficacy of certain chemotherapeutic drugs, making it a potential component in treating malignant tumors. Given its high efficacy, low toxicity, and multi-targeting characteristics, CA holds considerable promise as a therapeutic agent for cancer treatment. The objective of this review is to present a synthesis of the current understanding of the antitumor mechanism of CA and its research progress.
癌症仍然是肿瘤学领域的一项重大挑战,人们一直在寻找新的有效治疗方法。毛蕊异黄酮(CA)是一种源自中药的植物雌激素,作为一种有前景的候选药物受到了关注。凭借其高靶向性和低毒性,CA已在包括癌症、炎症和心血管疾病在内的各种疾病中展现出药用潜力。研究表明,CA对多种癌症具有抑制作用。其潜在的作用机制包括减少肿瘤细胞增殖、诱导肿瘤细胞凋亡以及抑制肿瘤细胞迁移和侵袭。此外,CA已被证明可增强某些化疗药物的疗效,使其成为治疗恶性肿瘤的潜在成分。鉴于其高效、低毒和多靶点特性,CA作为癌症治疗的治疗剂具有相当大的前景。本综述的目的是综合阐述目前对CA抗肿瘤机制及其研究进展的理解。